NIMG-17. VALIDATION OF DIFFUSION MRI AS AN IMAGING BIOMARKER FOR BEVACIZUMAB THERAPY IN RECURRENT GLIOBLASTOMA IN A RANDOMIZED PHASE III TRIAL OF BEVACIZUMAB WITH OR WITHOUT VB-111 (GLOBE)

BACKGROUND: Evidence from independent single center as well as multicenter phase II trials have suggested diffusion MRI is a strong predictive imaging biomarker for survival benefit in recurrent glioblastoma (rGBM) treated with anti-VEGF monotherapy, but not systemic chemotherapies or combination th...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Neuro Oncol
Main Authors: Ellingson, Benjamin, Cloughesy, Timothy, Wang, Chencai, Patel, Kunal, Raymond, Catalina, Brenner, Andrew, de Groot, John, Butowski, Nicholas, Zach, Leor, Campian, Jian, Schlossman, Jacob, Rizvi, Shan, Cohen, Yael, Lowenton-Spier, Noa, Minei, Tamar Rachmilewitz, Fain-Shmueli, Shifra, Wen, Patrick
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2020
Teme:
Neuroimaging
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651187/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.630
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki